Ionpath Inc
1455 Adams Dr
Menlo Park
CA
94025
United States
Tel: 650454-4093
11 articles about Ionpath Inc
-
Ionpath Announces Shift Toward Spatial Proteomics Services Business
5/24/2023
Ionpath, a pioneer in high-definition spatial proteomics, announced a rebalancing of the company’s focus toward its Spatial Proteomics Services.
-
Ionpath Names Goran Pljevaljcic as Chief Commercial Officer
11/1/2022
Ionpath, a pioneer in high-definition spatial proteomics, announced today that Goran Pljevaljcic has joined the company as its Chief Commercial Officer.
-
Ionpath Receives Strategic Investment to Support Spatial Proteomics Innovation
5/11/2022
Ionpath, Inc., a leader in high-definition spatial proteomics, announced that Thermo Fisher Scientific, the world leader in serving science, has made a strategic investment in the company.
-
Cell Publication Highlights Ionpath MIBI Spatial Proteomics Technology in Foundational Study Predicting Breast Cancer Progression
1/20/2022
Ionpath, Inc., the leader in high-definition spatial proteomics, today announced that a peer-reviewed research study led by scientists at Stanford University, Washington University, Duke University, and Arizona State University has been published in the journal Cell.
-
Ionpath Expands Biopharmaceutical Partnerships Program to Rapidly Deliver Novel Insights Utilizing the Company's High-Definition Spatial Proteomics Platform
8/26/2021
Ionpath, Inc. today announced a new program for biopharmaceutical research organizations interested in piloting spatial phenotyping analyses of tissue samples leveraging the company's Multiplexed Ion Beam Imaging (MIBI™) technology.
-
IONpath Closes $18 Million Series B Financing to Advance Precision Medicine
9/24/2020
IONpath, Inc., the leader in high-definition spatial proteomics, today announced the close of a $18 million Series B financing led by Samsara BioCapital, and included participation from new investor Bruker Corporation, a global leader in mass spectrometry.
-
IONpath Appoints Sander Gubbens, PhD, as Chief Executive Officer
8/20/2020
IONpath, Inc., the leader in high-definition spatial proteomics, today announced the appointment of Sander Gubbens, PhD, as its new CEO.
-
IONpath appoints Brad Nelson to its leadership team as Senior Vice President of Marketing and Corporate Strategy
6/17/2020
IONpath, Inc. the leader in multiplexed spatial tissue imaging and analysis, today announced the appointment of Brad Nelson to the position of Senior Vice President of Marketing and Corporate Strategy. Mr. Nelson will lead marketing, product management and application functions to meet the increasing demand for translational med
-
IONpath and Bristol Myers Squibb Jointly Author New Laboratory Investigation Article Exploring the Complexities of the Tumor Microenvironment
3/31/2020
IONpath, Inc. announces that they have jointly authored with Bristol Myers Squibb an article entitled Multiplexed Ion Beam Imaging for Characterization of the Tumor Microenvironment Across Tumor Types for the Nature journal Laboratory Investigation.
-
IONpath Launches Research Services Offering Multiplexed Tissue Analysis to Empower Pharmaceutical Discovery and Development Programs
2/11/2020
IONpath, Inc., today announces the launch of a dedicated service business providing access to their proprietary MIBIscope™ multiplexed imaging platform and its team of experts to support pharmaceutical and biotechnology companies working in immuno-oncology. IONpath has previously provi
-
IONpath Announces Commercial Launch of MIBIscope™—the First Multiplexed Ion Beam Imaging System
11/5/2019
MIBIscope allows researchers to visualize over 40 biomarkers simultaneously with high resolution, sensitivity, and throughput, and is compatible with standard tissue processing techniques